Analysis · Health
When Similar Blood Sugar Results Do Not Prove Two Drugs Match
By AWEI · AI-compiled · Published · Analysis prepared · 1 source · doi.org
Two diabetes drugs lowered HbA1c by almost the same amount, yet the trial could not establish that one was acceptably close to the other. DURATION-4, led by David Russell-Jones and colleagues, shows why similar averages do not settle a treatment comparison. The paper was accepted in 2011 and appeared in Diabetes Care’s February 2012 issue.
Researchers randomly assigned 820 adults with type 2 diabetes to weekly exenatide, metformin, pioglitazone or sitagliptin for 26 weeks. Participants had been inadequately controlled with diet and exercise. To keep treatment assignments hidden, everyone received both injections and tablets, with placebos matching whichever treatment they were not receiving.
Estimated average HbA1c reductions were 1.53 percentage points with exenatide, 1.48 with metformin, 1.63 with pioglitazone and 1.15 with sitagliptin. Exenatide met the trial’s noninferiority criterion against metformin and lowered HbA1c more than sitagliptin. Random assignment supports interpreting these comparisons as treatment effects within the trial, rather than simply associations.
The pioglitazone comparison was less conclusive. Researchers had specified a noninferiority margin of 0.3 percentage points. Although the average difference was only 0.10 points, the confidence interval extended to 0.35 points in pioglitazone’s favor. The data therefore did not rule out a disadvantage exceeding the chosen margin. Failing that test did not establish that exenatide was inferior.
Other outcomes added context: estimated weight fell by 2.0 kg with both exenatide and metformin, while rising by 1.5 kg with pioglitazone. No major hypoglycemic episodes occurred during treatment, but that observation cannot establish long-term safety. Only 696 participants completed treatment, and the researchers collected no specific adherence data.
Amylin Pharmaceuticals and Eli Lilly funded the study. Its selected population and 26-week duration limit conclusions about everyday use and lasting benefits or harms. The practical lesson is to read the uncertainty alongside the average: similar results can support different conclusions depending on how precisely they were measured.
Sources used for this article (1)
Direct links to the publisher reports used to prepare this article.
- Source 1
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) ['David Russell‐Jones', 'Robert Cuddihy', 'M Hanefeld', 'Ajay Kumar', 'José Gerardo González‐González', 'Melanie Chan', 'Anne M. Wolka', 'Marilyn K. Boardman', 'on behalf of the DURATION-4 Study Group
